With various target combinations and novel mechanisms of action, bispecific antibodies are presently recognized as a potent class of targeted therapies, with the potential to be used as treatment options for a variety of disease indications. Several pipeline candidates have recently entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.
To order this 370+ page report, which features 90+ figures and 110+ tables, please visit this – https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html
The USD 6.9 billion financial opportunity (by 2030) within the bispecific antibody therapeutics market has been analyzed across the following segments:
Therapeutic Area
- Autoimmune Disorders
- Eye Disorders
- Genetic Disorders
- Hematological Malignancies
- Infectious Diseases
- Inflammatory Disorders
- Skin Disorders
Mechanism of Action
- Cytokines Retargeting / Neutralization
- Dual Ligands Blocking
- T-cell Retargeting / Activation
- Others
Target Antigens
- CD3 x CD19
- CD30 x CD16A
- Factor IXa x Factor X
- IL-1α x IL-1β
- IL-13 x IL-4
- IL-17A x Albumin
- IL-17A x IL-17F
- Psl x PcrV
- VEGF-A x ANG2
- Others
Antibody Formats
- Asymmetric
- Fragments
- Symmetric
- Others
Key Geographical Regions
- North America
- Europe
- Asia-Pacific
The Bispecific Antibody Therapeutics Market (4th Edition), 2020-2030 report features the following companies, which we identified to be key players in this domain:
- Amgen
- Ablynx
- AbbVie
- Affibody
- Affimed
- Alphamab
- AstraZeneca
- Avillion
- Chugai Pharmaceuticals
- Eddingpharm
- GSK
- Merck
- Merus
- Roche
- Regeneron Pharmaceuticals
- Taisho Pharmaceuticals
- Zymeworks
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Market Overview
5. Bispecific Antibody Therapeutics: Technology Platforms
6. Drug Profiles
7. Key Insights
8. Benchmark Analysis: Big Pharma Players
9. Partnerships and Collaborations
10. Contract Services for Bispecific Antibody Therapeutics
11. Clinical Trial Analysis
12. Case Study: Regulatory Guidelines for Bispecific Antibodies
13. Case Study: Promotional / Marketing Strategies
14. SWOT Analysis
15. Market Forecast and Opportunity Analysis
16. Concluding Remarks
17. Executive Insights
18. Appendix 1: Tabulated Data
19. Appendix 2: List of Companies and Organizations
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
